FDA Should Beef Up Post-Market Drug Safety: GAO
The U.S. Food and Drug Administration still has weaknesses in its post-market oversight of drugs, the U.S. Government Accountability Office said Wednesday, three years after finding that the FDA needed to...To view the full article, register now.
Already a subscriber? Click here to view full article